open access

Vol 50, No 4 (2012)
Original paper
Submitted: 2012-10-01
Accepted: 2012-11-14
Published online: 2012-12-23
Get Citation

Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: clinicoimmunohistochemical and histogenetic characteristics

Witold Kędzia, Dominik Pruski, Kinga Iwaniec, Marcin Przybylski, Zbigniew Friebe, Helena Rajpert-Kędzia
DOI: 10.5603/FHC.2012.0072
·
Folia Histochem Cytobiol 2012;50(4):513-518.

open access

Vol 50, No 4 (2012)
ORIGINAL PAPERS
Submitted: 2012-10-01
Accepted: 2012-11-14
Published online: 2012-12-23

Abstract

Aims: To search for favorable prognostic factors in CS on the basis of clinical, morphological and immunocytochemical data, while simultaneously considering  histogenesis of this neoplasm.

Methods and Results: Thirty two uterine CS patients were analyzed based on clinical and morphological data. In addition, each specimen was immunohistochemically stained with appropriately selected antibodies characterizing relevant types of cells and tissues. The presence of both carcinomatous and sarcomatous patterns was observed in all tumors. Among carcinomatous patterns, endometrioid carcinoma was most common, while serous, clear cell, and undifferentiated were less common. Among sarcomatous patterns, endometrioid sarcomas represented the largest group, while leiomyosarcomas, chondrosarcomas, fibrosarcomas, osteosarcomas, rhabdosarcomas were rarely observed. Mitotic activity was evidently higher in carcinomas. Among seven neoplasms  the expression of both cytokeratin and vimentin was noted in cells of carcinomatous patterns.

Conclusions: This study shows that an early diagnosis (stage I-II) and an initial aggressive surgical cytoreduction are favorable prognostic factors in CS. Furthermore, cytokeratin-vimentin positive cells in carcinomatous patterns suggest sarcomatous metaplasia of adenocarcinoma. Unfortunately, the study did not identify histological structures of prognostic value.

Abstract

Aims: To search for favorable prognostic factors in CS on the basis of clinical, morphological and immunocytochemical data, while simultaneously considering  histogenesis of this neoplasm.

Methods and Results: Thirty two uterine CS patients were analyzed based on clinical and morphological data. In addition, each specimen was immunohistochemically stained with appropriately selected antibodies characterizing relevant types of cells and tissues. The presence of both carcinomatous and sarcomatous patterns was observed in all tumors. Among carcinomatous patterns, endometrioid carcinoma was most common, while serous, clear cell, and undifferentiated were less common. Among sarcomatous patterns, endometrioid sarcomas represented the largest group, while leiomyosarcomas, chondrosarcomas, fibrosarcomas, osteosarcomas, rhabdosarcomas were rarely observed. Mitotic activity was evidently higher in carcinomas. Among seven neoplasms  the expression of both cytokeratin and vimentin was noted in cells of carcinomatous patterns.

Conclusions: This study shows that an early diagnosis (stage I-II) and an initial aggressive surgical cytoreduction are favorable prognostic factors in CS. Furthermore, cytokeratin-vimentin positive cells in carcinomatous patterns suggest sarcomatous metaplasia of adenocarcinoma. Unfortunately, the study did not identify histological structures of prognostic value.

Get Citation
About this article
Title

Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus: clinicoimmunohistochemical and histogenetic characteristics

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 50, No 4 (2012)

Article type

Original paper

Pages

513-518

Published online

2012-12-23

DOI

10.5603/FHC.2012.0072

Bibliographic record

Folia Histochem Cytobiol 2012;50(4):513-518.

Authors

Witold Kędzia
Dominik Pruski
Kinga Iwaniec
Marcin Przybylski
Zbigniew Friebe
Helena Rajpert-Kędzia

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl